232 related articles for article (PubMed ID: 28319496)
1. The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer.
Demirkol MO; Kiremit MC; Acar O; Ucar B; Saglican Y
Clin Nucl Med; 2017 May; 42(5):403-405. PubMed ID: 28319496
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT.
Usmani S; Ahmed N; Marafi F; Rasheed R; Amanguno HG; Al Kandari F
Clin Nucl Med; 2017 May; 42(5):410-413. PubMed ID: 28240661
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
4. Epididymal Metastasis of Prostate Cancer Detected With 68Ga-PSMA-PET/CT.
Serfling S; Luther A; Kosmala A; Bluemel C
Clin Nucl Med; 2016 Oct; 41(10):792-3. PubMed ID: 27355849
[TBL] [Abstract][Full Text] [Related]
5.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
6. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
7.
Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
[No Abstract] [Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
[TBL] [Abstract][Full Text] [Related]
10. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer.
Aydin F; Akçal A; Ünal B; Sezgin Göksu S; Güngör F
Clin Nucl Med; 2017 May; 42(5):358-360. PubMed ID: 28240656
[TBL] [Abstract][Full Text] [Related]
12. Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
Bilgin R; Ergül N; Çermik TF
Clin Nucl Med; 2016 Dec; 41(12):956-958. PubMed ID: 27824323
[TBL] [Abstract][Full Text] [Related]
13. 68Ga PSMA PET/CT in a Rare Case of Metastatic Adenocarcinoma Prostate Presenting as Numb Chin Syndrome.
Sasikumar A; Joy A; Pillai MR; Gopal R; Thomas B
Clin Nucl Med; 2017 Mar; 42(3):e161-e162. PubMed ID: 28045729
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
15. Demonstration of Response to Androgen Deprivation Therapy by 68Ga-PSMA PET/CT.
Soydal C; Ozkan E; Kaya B; Kucuk ON
Clin Nucl Med; 2016 Oct; 41(10):794-6. PubMed ID: 27454599
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
17. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
18.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
19.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
20. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
